Takeda and Arrowhead Collaboration | ARWR Message Board Posts

Arrowhead Pharmaceuticals, Inc.

  ARWR website

ARWR   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  10164 of 10169  at  10/8/2020 8:34:35 AM  by

Steve_382


 In response to msg 10163 by  CHM_760
view thread

Re: Takeda and Arrowhead Collaboration

 
 

Takeda, Arrowhead in Liver-Disease Collaboration and Licensing Deal

DOW JONES & COMPANY, INC. 8:26 AM ET 10/8/2020
Symbol Last Price Change
TAK 17.29down 0 (0%)
QUOTES AS OF 04:10:00 PM ET 10/07/2020

Takeda Pharmaceutical Company Ltd. (TAK) and Arrowhead Pharmaceuticals Inc. said they are in a collaboration and licensing agreement to develop ARO-AAT to treat alpha-1 antitrypsin-associated liver disease.

Takeda and Arrowhead will co-develop ARO-AAT which, if approved, would be co-commercialized in the U.S. under a 50/50 profit-sharing structure. Outside the U.S., Takeda would lead global commercialization and receive an exclusive license to commercialize ARO-AAT, with Arrowhead eligible to receive tiered royalties of 20%-25% on net sales.

Arrowhead will receive an upfront payment of $300 million and can get potential development, regulatory and commercial milestones up to $740 million.

Arrowhead shares were up 5% premarket, to $50.30.

"AAT-associated liver disease is a devastating condition for which there are no approved therapies. With its RNAi- based mechanism of action, ARO-AAT has the potential to treat the underlying cause of AATLD, thereby helping patients avoid the need for liver transplantation and associated co-morbidities," said Asit Parikh, head of the gastroenterology therapeutic area unit at Takeda.

Alpha-1 antitrypsin-associated deficiency is a rare genetic disorder associated with liver disease in children and adults and pulmonary disease in adults.

Write to Michael Dabaie at michael.dabaie@wsj.com

  (END) Dow Jones Newswires   10-08-200826ET   Copyright (c) 2020 Dow Jones & Company, Inc. 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 3     Views: 190
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board








Financial Market Data provided by
.
Loading...